TY - JOUR AU - Maltsev , Дмитро AU - Stefanyshyn , Володимир PY - 2023/01/08 Y2 - 2024/03/29 TI - EFFECTIVENESS OF COMBINED IMMUNOTHERAPY WITH PROPES AND INFLAMAFERTIN FOR SELECTIVE DEFICIENCY OF NK AND NKT CELLS IN CHILDREN WITH AUTISM SPECTRUM DISORDERS ASSOCIATED WITH GENETIC DEFICIENCY OF THE FOLATE CYCLE JF - Actual Problems of Nephrology JA - APN VL - IS - 30-31 SE - Articles DO - 10.37321/nefrology.2022.30-31-05 UR - https://apn.org.ua/index.php/journal/article/view/59 SP - 45-51 AB - <p><strong>Backgrounds.</strong> The results of preliminary small clinical studies indicate the potential benefit of combined immunotherapy with Propes and Inflamafertin to compensate for NK and NKT cell deficiency caused by genetic deficiency of the folate cycle in children with autism spectrum disorders.</p><p><strong>The aim of the study:</strong> to study the effectiveness of combined immunotherapy with Propes and Inflamafertin for NK- and NKT-cell deficiency in children with autism spectrum disorders associated with genetic deficiency of the folate cycle.</p><p><strong>Materials and methods.</strong> In this single-center, prospective, controlled, non-randomized clinical trial, 96 children aged 2 to 10 years with autism spectrum disorders associated with genetic deficiency of the folate cycle participated (study group, SH). SH children received Propes at a dose of 2 ml i/m every other day at night for 3 months (45 injections) and Inflamafertin at a dose of 2 ml i/m every other day at night for 3 months, alternating with Propes (45 injections actions). The control group (CG) consisted of 32 children of a similar age and gender distribution who suffered from autism spectrum disorders associated with a genetic deficiency of the folate cycle, but did not receive immunotherapy.</p><p><strong>Results and their discussion.</strong> The number of NK cells reached the lower limit of normal range in 39 of 53 patients (74% of cases) with an initial deficiency of these lymphocytes, and the average number of NK cells in the blood in the SH increased almost twice during the 3-month course of immunotherapy (p&lt;0.05; Z&lt;Z0.05), but returned almost to the initial level during the next 2 months after withdrawal of immunotherapeutic agents (р&gt;0.05; Z&gt;Z0.05). The number of NKT cells normalized in 78 of 87 patients (89% of cases) with an initial deficiency of these cells, and the average number of NKT cells in the blood in the SH increased by half during the course of immunotherapy (p&lt;0.05; Z&lt;Z0.05) and continued to increase during the next 2 months after withdrawal of immunotropic drugs (р&lt;0.05; Z&lt;Z0.05). There was a correlation between immunotherapy and normalization of the number of NK- (χ2=18.016; OR=13.929; 95%CI=3.498-55.468) and NKT-cells (χ2=60.65; OR=46.800; 95%CI=14.415-151.937) in the blood with a strong connection between these processes (criterion φ=0.504 and 0.715, respectively; C=0.450 and 0.581, respectively).</p><p><strong>Conclusions.</strong> Combined immunotherapy with Propes and Inflamafertin is an effective strategy for the treatment of immunodeficiency caused by genetic deficiency of the folate cycle in children with autism spectrum disorders.</p> ER -